Are peptides really worth it? What the science says
Quick answer
Selank is a synthetic heptapeptide analog of tuftsin with proposed anxiolytic mechanisms involving serotonergic, GABAergic, and BDNF pathways, supported primarily by Russian preclinical and small human trial data. It is not FDA-approved and is only legally available in the US through licensed compounding pharmacies with a valid prescription. The evidence for its use in ADHD, PTSD, and cognitive decline specifically is not established in peer-reviewed human trials.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @nicolestroopnp actually say?
Nicole Stroop, a self-described functional medicine and peptide-certified nurse practitioner, made a strong personal claim: this peptide "has absolutely changed my life for anxiety." The peptide in question is Selank, a synthetic heptapeptide developed in Russia. She argues it works by modulating serotonin, dopamine, norepinephrine, and GABA, while also supporting brain-derived neurotrophic factor (BDNF) and reducing neuroinflammation. She listed candidate populations including people with anxiety, ADHD, PTSD, cognitive decline, and stress-related sleep issues. She closed with a reasonable caution: skip online sources and go through a compounding pharmacy via a qualified provider. That last part is good advice. The mechanistic claims in the middle, though, deserve a closer look.
Does the science back this up?
Partially, yes, but the evidence base is thin and almost entirely preclinical or from small Russian trials. Selank has real mechanistic data behind it, but calling it proven for anxiety in humans is a stretch at this stage of research.
Selank is a synthetic analog of tuftsin, and most of the published mechanistic work comes from Russian institutions, particularly the Institute of Molecular Genetics. Seredenin and Voronina (2009, Eksperimental'naya i Klinicheskaya Farmakologiya) documented anxiolytic effects in animal models with effects on serotonin and GABA-ergic tone. A small human trial by Zozulya et al. (2008, Bulletin of Experimental Biology and Medicine) showed reduced anxiety scores in patients with generalized anxiety disorder versus placebo, but the sample sizes were modest and independent replication is essentially nonexistent. The BDNF claim has some support from rodent studies showing Selank upregulates BDNF expression in hippocampal tissue, but translating that to human cognition and stress resilience is a significant inferential leap. Western peer-reviewed replications are sparse.
What did they get wrong (or right)?
Nicole got the general mechanism directionally correct but oversimplified it in ways that could mislead patients. She also made several candidate population claims that go well beyond what the current evidence supports.
What she got right: the serotonergic and GABAergic mechanisms are the most documented in available Selank literature. The GABA-modulatory effect, specifically its influence on GABA-A receptor sensitivity, is reasonably supported in preclinical work (Kolik et al., 2014, Bulletin of Experimental Biology and Medicine). Her sourcing advice, meaning compound pharmacy through a licensed provider, is genuinely correct and clinically responsible.
What she got wrong, or at least overstated:
- Calling serotonin "our happy neurotransmitter" is a persistent pop-science myth. Serotonin's role in mood is far more complex and contested than that framing suggests (Moncrieff et al., 2022, Molecular Psychiatry).
- Listing ADHD, PTSD, and cognitive decline as appropriate use cases goes beyond what any current clinical evidence for Selank supports. There are no robust human RCTs for Selank in these conditions.
- Describing dopamine as driving "focus and reward" as if this is straightforward ignores the complexity of dopaminergic circuits and may set unrealistic expectations.
- The anti-neuroinflammatory claim is plausible based on cytokine studies (Filatova et al., 2012, Russian Journal of Bioorganic Chemistry), but framing it as something that "directly" lowers inflammatory molecules causing neuroinflammation overstates certainty.
What should you actually know?
Selank is a genuinely interesting compound with a reasonable mechanistic rationale for anxiety. But interesting is not the same as proven, and this distinction matters when you are deciding whether to use it.
Here is what the honest picture looks like. Selank is not FDA-approved for any indication. It is available in the US only through compounding pharmacies operating under 503A or 503B frameworks, which means quality and sterility vary by pharmacy. The existing human trial data comes almost exclusively from Russian research groups with no independent replication in Western journals. That is not automatically disqualifying, but it means the evidence hierarchy is sitting at the bottom of the pyramid.
Personal testimonials from practitioners, even well-credentialed ones, are not a substitute for controlled trial data. Nicole saying it "absolutely changed my life" is her experience. It is not a clinical outcome measure. If you are considering Selank for anxiety, the reasonable move is a thorough conversation with a licensed provider who can assess your full clinical picture, not a TikTok comment asking for a protocol.
One thing Nicole did not address: Selank's tolerability profile. The available literature suggests it is generally well tolerated, but drug interactions and contraindications have not been studied adequately in diverse human populations. That gap matters.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Are peptides really worth it? What the science says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Functional Connectomic Approach to Studying Selank and Semax Effects
Small Russian fMRI study (52 healthy volunteers) of brain connectivity after Semax or Selank; mechanistic and exploratory, not a clinical efficacy trial.
PubMed
Effects of Semax on the Default Mode Network of the Brain
Small human fMRI study (24 adults) of intranasal Semax on brain networks; an imaging-marker study with no clinical outcomes, not replicated outside the originating group.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Are peptides really worth it? What the science says is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
Selank is a synthetic heptapeptide analog of tuftsin with proposed anxiolytic mechanisms involving serotonergic, GABAergic, and BDNF pathways, supported primarily by Russian preclinical and small human trial data.
FormBlends verdict
Selank is a synthetic heptapeptide analog of tuftsin with proposed anxiolytic mechanisms involving serotonergic, GABAergic, and BDNF pathways, supported primarily by Russian preclinical and small human trial data. It is not FDA-approved and is only legally available in the US through licensed compounding pharmacies with a valid prescription. The evidence for its use in ADHD, PTSD, and cognitive decline specifically is not established in peer-reviewed human trials.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Selank is a synthetic heptapeptide analog of tuftsin with proposed anxiolytic mechanisms involving serotonergic, GABAergic, and BDNF pathways, supported primarily by Russian preclinical and small human trial data. It is not FDA-approved and is only legally available in the US through licensed compounding pharmacies with a valid prescription. The evidence for its use in ADHD, PTSD, and cognitive decline specifically is not established in peer-reviewed human trials.
- Selank is not FDA-approved for any condition; it is legally available in the US only through compounding pharmacies with a prescription from a licensed provider.
- The most rigorous human trial data for Selank (Zozulya et al., 2008, Bulletin of Experimental Biology and Medicine) involved small sample sizes and has not been independently replicated in Western peer-reviewed journals.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Selank is not FDA-approved for any condition; it is legally available in the US only through compounding pharmacies with a prescription from a licensed provider.
- The most rigorous human trial data for Selank (Zozulya et al., 2008, Bulletin of Experimental Biology and Medicine) involved small sample sizes and has not been independently replicated in Western peer-reviewed journals.
- Calling serotonin the 'happy neurotransmitter' contradicts current neuroscience; a 2022 umbrella review in Molecular Psychiatry (Moncrieff et al.) found no consistent evidence that low serotonin causes depression.
- Selank's GABAergic mechanism is the best-supported claim in the video, based on preclinical work by Kolik et al. (2014), but animal data does not automatically translate to human clinical outcomes.
- Using Selank for ADHD, PTSD, or cognitive decline is not supported by any robust human clinical trial evidence as of the current published literature.
- Practitioner testimonials, including from credentialed NPs, are not a substitute for controlled trial data and should not be treated as evidence of efficacy.
- Quality and sterility of compounded peptides vary by pharmacy; sourcing through a reputable 503A or 503B compounding facility, as Nicole recommends, is the minimum standard for safety.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Nicole FNP, IFMCP · TikTok creator
10.0K views on this video
Are peptides really worth it? I think so! #functionalnursepractitioner #nicolestroopnp #functionalnp #peptidetherapy
Sources & references
- [1]Zozulya et al. (2008)
- [2]Kolik et al., 2014
- [3]Moncrieff et al., 2022
- [4]Filatova et al., 2012
- [5]Seredenin and Voronina (2009)
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Nicole FNP, IFMCP, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.